Barrie M. Weinstein, MD, CCD joined the faculty at The Mount Sinai Medical Center in July. 2010 with an appointment in the Division of Endocrinology. She is a board-certified endocrinologist, internist and nutrition-support physician. After graduating from the Sackler School of Medicine in Tel Aviv, Israel, she completed her Internship and Residency in Internal Medicine at The Mount Sinai School of Medicine. After completing her Residency in 2007, she served as a post-doc research fellow at Mount Sinai in the Division of Endocrinology, where she focused on the effects of COX-2 inhibitors and PGE2 on bone. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2010.
Dr. Weinstein is part of the Bone Densitometry Program at Mount Sinai, interpreting bone density reports.
MD, Sackler School of Medicine
Residency, Internal Medicine
Mount Sinai Hospital
Mount Sinai Hospital
American Board of Physician Nutrition Specialists
American Board of Internal Medicine
Weinstein BM, Epstein S. Drug and hormone effects on Vitamin D metabolism. In: Feldman D, Pike JW, Adams JS, editors. Vitamin D, Third Edition.. Academic Press; 2011.; pp1245-1290.
Weinstein BM, Kirschenbaum A, Janout V, Regen SL, Yao S, Levine AC. Development of New Compounds Specifically Targeting Prostate Cancer Bone Metastases. .;.
Liu XH, Kirschenbaum A, Weinstein BM, Zaidi M, Yao S, Levine AC. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochemical and biophysical research communications 2010 Apr; 394(3).
Weinstein BM, Levine AC, Kim M, Skamagas M. Adrenal Histoplasmosis Diagnosed by Endoscopic Ultrasound Guided FNA of the Left Adrenal: A Review of the Literature of Histoplasmosis of the Adrenals and EUS-guided FNA..;.
Weinstein BM, Liu X, Yao S, Kirschenbaum A, Levine AC. Dose-Dependent Effects of PGE2 on Osteoblasts: Implications for Osteoporosis Treatment..;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Weinstein did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.